THE "NEW" PROSTATE CANCER INFOLINK

We have heard from one of our contacts that Bayer Healthcare (presumably in combination with their business partner, Algeta) is initiating an expanded access (compassionate use) trial of injectable radiation therapy with radium-223 chloride (Alpharadin^®) for men with metastatic, castration-resistant prostate cancer (mCRPC).

The full details of this trial are available on the ClinicalTrials.gov web site. There is no listing (yet) of centers where patients can be enrolled into this trial. However, an e-mail address is available through which patients who may be interested in enrolling in this trial can contact trial managers at Bayer Healthcare.

If you are interested in finding out more about this trial, we suggest you use that e-mail address to contact Bayer Healthcare and send an e-mail that looks something like the following:

Heading: Inquiry about Alpharadin trial for metastatic, castration-resistant prostate cancer

Text: Please send me more information about the expanded access trial of radium-223 chloride (Alpharadin) for men with metastatic CRPC. I am particularly interested in being able to confirm my eligibility for this study and centers where I may be able to be treated. I live in [city, state, country]. I can be contacted by e-mail at [insert e-mail address] or by telephone at [insert phone number].

As previously reported, radium-223 choride has demonstrated a small but significant overall survival benefit when used in the treatment of men with symptomatic mCRPC. It will probably be approved for use in the treatment of mCRPC some time later this year (in both the USA and Europe), but participation in this expanded access trial will allow eligible patients to get early access to the drug at no cost (at least for a period of time).

Filed under: Drugs in development, Management, Treatment | Tagged: access, Alpharadin, expanded, mCRPC, radium-223 |